{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-135767","form_type":"8-K","ticker":"FBRX","cik":"0001419041","company_name":"Forte Biosciences, Inc.","filed_at":"2026-04-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.259000+00:00","generated_at":"2026-05-15T07:57:45.674384+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Forte Biosciences reports FY2025 net loss $69.4M, cash $77M; celiac Phase 2 data due 2026","bullets":["Net loss $69.4M ($4.71/shr) vs $35.5M ($12.17/shr) in 2024; R&D expenses $58.2M, up from $21.2M.","Cash and equivalents $77.0M at Dec 31, 2025, up from $22.2M at Dec 31, 2024.","Phase 2 celiac disease topline data expected in 2026; Phase 1b vitiligo (1H 2026) and alopecia areata data expected in 2026.","Weighted average shares & pre-funded warrants 14.7M vs 2.9M in 2024; CEO highlights FB102 potential in multi-billion markets."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-135767","json":"https://secwatch.observer/filing/0001193125-26-135767.json","markdown":"https://secwatch.observer/filing/0001193125-26-135767.md","text":"https://secwatch.observer/filing/0001193125-26-135767.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419041/000119312526135767/0001193125-26-135767-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419041/000119312526135767/d63145d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:57:45.674384+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f3b5e6449b7e972bac9dfb3bfed84099aa313b08","claim":"Forte Biosciences, Inc. reported the year ended December 31, 2025 results: net income $(69,375) thousand, EPS $(4.71).","evidence_excerpt":"Interest income 2,715 1,314 Other expense, net (396 ) (190 ) Total other income, net 2,319 1,124 Net loss before taxes (68,338 ) (35,478 ) Income tax expense 1,037 — Net loss $ (69,375 ) $ (35,478 ) Per share information: Net loss per share - basic and diluted $ (4.71 ) $ (12.17 ) Weighted average share, and pre-funded warrants outstanding, basic and diluted","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1419041/000119312526135767/0001193125-26-135767-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Net income","value":"$(69,375) thousand"},{"label":"EPS","value":"$(4.71)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}